Freedom of Information Request: Our Reference CTMUHB_393_23

You asked:

We are analysing the usage of biologic and biosimilar products within Rheumatology. It would be really helpful if you could provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

- Abatacept [Orencia]
- Adalimumab [Humira]
- Adalimumab Biosimilars
- Apremilast [Otezla]
- Baricitinib [Olumiant]
- Bimekizumab [Bimzelx]
- Certolizumab [Cimzia]
- Etanercept [Enbrel]
- Etanercept Biosimilars
- Filgotinib [Jyseleca]
- Golimumab [Simponi]
- Guselkumab [Tremfya]
- Infliximab [Remicade]
- Infliximab Biosimilars
- Ixekizumab [Taltz]
- Risankizumab [Skyrizi]
- Rituximab [MabThera]
- Rituximab Biosimilars
- Sarilumab [Kevzara]
- Secukinumab [Cosentyx]
- Tocilizumab [Ro Actemra]
- Tofacitinib [Xeljanz]
- Upadacitinib [Rinvoq]
- Ustekinumab [Stelara]

Our response:

Please see provided below a table populated with the data that Medicines Management are able to provide. The period relates to the last 3 months available which is 1st June 2023 to 31st August 2023.

Medicine	**Number of Patients**
Abatacept [Orencia]	53
Adalimumab [Humira]	74
Adalimumab Biosimilars	358
Apremilast [Otezla]	15
Baricitinib [Olumiant]	35
Bimekizumab [Bimzelx]	0
Certolizumab [Cimzia]	57
Etanercept [Enbrel]	27
Etanercept Biosimilars	299

Filgotinib [Jyseleca]	5
Golimumab [Simponi]	58
Guselkumab [Tremfya]	**
Infliximab [Remicade]	**
Infliximab Biosimilars	22
Ixekizumab [Taltz]	13
Risankizumab [Skyrizi]	0
Rituximab [MabThera]	**
Rituximab Biosimilars	35
Sarilumab [Kevzara]	6
Secukinumab [Cosentyx]	80
Tocilizumab [Ro Actemra]	84
Tofacitinib [Xeljanz]	11
Upadacitinib [Rinvoq]	15
Ustekinumab [Stelara]	13

Where the figures are less than 5, this has been denoted by **. The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR**.** We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.